SLC7A11 and pancreatic neoplasm: Similarly, Yang and his team have established that SLC7A11-AS1 knockdown would promote NRF2 degradation, ultimately leading to an increase in ROS levels and the sensitivity to gemcitabine in pancreatic cancer (Yang et al., 2020).